International clinical psychopharmacologyAug 2, 2026

Potential safety concerns and monitoring advice for lithium and GLP-1 treatments in bipolar disorder

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Aug 3, 2026

Abstract

Six reports since 2025 indicate potential lithium elevation or toxicity associated with glucagon-like peptide-1 (GLP-1) receptor agonists.

Elevated lithium levels may occur after the initiation, switching, or escalation of GLP-1 receptor agonists.
An uncontrolled pharmacovigilance signal suggests a possible drug interaction that increases lithium concentrations.
Candidate mechanisms include delayed gastric emptying affecting absorption and reduced clearance of lithium after weight loss.
Acute toxicity events are likely influenced by intake and volume changes, while a sustained increase in lithium concentration per dose remains unexplained.
The temporal model proposed is speculative and may be subject to ascertainment bias.

Simplified

Lithium remains a cornerstone of bipolar disorder treatment, yet it has a narrow-therapeutic index and depends on renal and volume status. Glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 agonists are now widely coprescribed in this population. Six bibliographically distinct reports published since 2025 describe lithium elevation or toxicity after initiation, switching, or escalation, and in June 2026 the European Medicines Agency's Pharmacovigilance Risk Assessment Committee opened a signal of a drug interaction leading to increased lithium levels. We separate three levels of evidence: (a) an uncontrolled pharmacovigilance signal; (b) plausible mechanistic pathways; and (c) a speculative temporal model. The candidate mechanisms are more constrained than previously appreciated: delayed gastric emptying alters absorption rate without demonstrably altering total exposure; GLP-1-mediated natriuresis acts in the opposite direction and does not persist; reduced lithium clearance after weight loss is sustained but quantitatively insufficient. The temporal framing is speculative and may partly reflect ascertainment bias. The reports describe two separable phenomena: acute toxicity events, largely explicable by intake and volume effects, and a sustained upward shift in concentration per unit dose, which is not. We set out falsifiable predictions and monitoring considerations, adopting rather than claiming the schedule proposed elsewhere.

Full Text

Full text is available at the source.

View Full Text ↗

Potential safety concerns and monitoring advice for lithium and GLP-1 treatments in bipolar disorder

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief